Dean Tantin, Ph.D

Dean Tantin, Ph.D. Scientific Advisory Board Member, Praespero Professor, Department of Pathology, University of Utah School of Medicine; Member, Nuclear Control of Cell Growth and Differentiation Program, Huntsman Cancer Institute
Key Achievements
Recipient of the John Weis Faculty Award in Experimental Pathology (2025), awarded by the University of Utah Department of Pathology
Praespero Innovation Award winner (2018) for research on genetic and pharmacological targeting of OCA-B in autoimmunity
Showed that the transcription factor Oct1 and its cofactor OCA-B play key roles in T cell memory and autoimmunity, positioning OCA-B as a promising drug target
Leveraged Praespero pilot data into a funded NIH R01 grant of nearly $2 million
Initiated a drug discovery pipeline for small molecules that modulate OCA-B activity
ABOUT
Dean Tantin is a molecular biologist whose research explores how cells decide which genes to turn on and off, and how those decisions shape immunity, stem cell biology, and cancer. His lab discovered that the transcription factor Oct1 and its specialized cofactor OCA-B help regulate T cell memory and autoimmunity. This work has made OCA-B a promising therapeutic target for diseases such as type 1 diabetes and multiple sclerosis, with the potential to calm harmful immune responses without fully compromising a patient's defenses. His widely cited work on the interplay between Oct1 and Oct4 has also advanced understanding of cellular pluripotency, stem cell self-renewal, and cancer.
With Praespero's funding, Dr. Tantin's team uncovered an antirepressor protein that, unlike typical on-off transcription regulators, keeps certain genes from being permanently silenced. Removing it in mouse models of relapsing-remitting multiple sclerosis left the initial disease and viral control intact but specifically altered relapses, a finding the team had not seen before in these models. This suggests a mechanism that could inform future therapies for diseases marked by relapses or flares. The early support helped him overcome the "pivot penalty" of moving from pure immunology into autoimmune research, and the pilot data became the foundation of a nearly $2 million NIH R01 grant, multiple publications, and a drug discovery effort aimed at small-molecule treatments. More recently, his lab has begun characterizing previously unstudied fat cells in the thymus, the organ where T cells develop, to better understand how thymic function declines with age.
Dr. Tantin earned his B.S. in Molecular Biology from the University of California, San Diego, and his Ph.D. in Molecular Biology from UCLA. He then completed a postdoctoral fellowship at MIT under Nobel Laureate Phillip Sharp. Since joining the University of Utah in 2006, he has trained generations of graduate and medical students in immunology, gene expression, and cancer biology. On Praespero's Scientific Advisory Board, he brings the pioneering, boundary-pushing thinking that Praespero exists to support.
